000128095 001__ 128095 000128095 005__ 20241125101159.0 000128095 0247_ $$2doi$$a10.1016/j.euroneuro.2023.06.003 000128095 0248_ $$2sideral$$a135272 000128095 037__ $$aART-2023-135272 000128095 041__ $$aeng 000128095 100__ $$aGonzález Segura, Àlex 000128095 245__ $$aThe polygenic basis of relapse after a first episode of schizophrenia 000128095 260__ $$c2023 000128095 5060_ $$aAccess copy available to the general public$$fUnrestricted 000128095 5203_ $$aLittle is known about genetic predisposition to relapse. Previous studies have linked cognitive and psychopathological (mainly schizophrenia and bipolar disorder) polygenic risk scores (PRS) with clinical manifestations of the disease. This study aims to explore the potential role of PRS from major mental disorders and cognition on schizophrenia relapse. 114 patients recruited in the 2EPs Project were included (56 patients who had not experienced relapse after 3 years of enrollment and 58 patients who relapsed during the 3-year follow-up). PRS for schizophrenia (PRS-SZ), bipolar disorder (PRS-BD), education attainment (PRS-EA) and cognitive performance (PRS-CP) were used to assess the genetic risk of schizophrenia relapse.Patients with higher PRS-EA, showed both a lower risk (OR=0.29, 95% CI [0.11–0.73]) and a later onset of relapse (30.96± 1.74 vs. 23.12± 1.14 months, p=0.007. Our study provides evidence that the genetic burden of neurocognitive function is a potentially predictors of relapse that could be incorporated into future risk prediction models. Moreover, appropriate treatments for cognitive symptoms appear to be important for improving the long-term clinical outcome of relapse. 000128095 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI08-0208$$9info:eu-repo/grantAgreement/ES/MINECO/PI11-00325$$9info:eu-repo/grantAgreement/ES/MINECO/PI16-00612 000128095 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/ 000128095 590__ $$a6.1$$b2023 000128095 592__ $$a1.756$$b2023 000128095 591__ $$aCLINICAL NEUROLOGY$$b22 / 280 = 0.079$$c2023$$dQ1$$eT1 000128095 593__ $$aBiological Psychiatry$$c2023$$dQ1 000128095 591__ $$aPSYCHIATRY$$b21 / 279 = 0.075$$c2023$$dQ1$$eT1 000128095 593__ $$aNeurology$$c2023$$dQ1 000128095 591__ $$aPHARMACOLOGY & PHARMACY$$b26 / 354 = 0.073$$c2023$$dQ1$$eT1 000128095 593__ $$aPsychiatry and Mental Health$$c2023$$dQ1 000128095 591__ $$aNEUROSCIENCES$$b32 / 310 = 0.103$$c2023$$dQ1$$eT1 000128095 593__ $$aPharmacology$$c2023$$dQ1 000128095 593__ $$aPharmacology (medical)$$c2023$$dQ1 000128095 593__ $$aNeurology (clinical)$$c2023$$dQ1 000128095 594__ $$a10.3$$b2023 000128095 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000128095 700__ $$aProhens, Llucia 000128095 700__ $$aGassó, Patricia 000128095 700__ $$aRodríguez, Natalia 000128095 700__ $$aGarcia-Rizo, Clemente 000128095 700__ $$aMoreno-Izco, Lucía 000128095 700__ $$aAndreu-Bernabeu, Álvaro 000128095 700__ $$aZorrilla, Iñaki 000128095 700__ $$aMane, Anna 000128095 700__ $$aRodríguez-Jiménez, Roberto 000128095 700__ $$aRoldán, Alexandra 000128095 700__ $$aSarró, Salvador 000128095 700__ $$aIbáñez, Ángela 000128095 700__ $$aUsall, Judith 000128095 700__ $$aSáiz, Pilar A 000128095 700__ $$aCuesta, Manuel J. 000128095 700__ $$aParellada, Mara 000128095 700__ $$aGonzález-Pinto, Ana 000128095 700__ $$aBerrocoso, Ester 000128095 700__ $$aBernardo, Miquel 000128095 700__ $$aMas, Sergi 000128095 700__ $$aMezquida, Gisela 000128095 700__ $$aArbelo, Néstor 000128095 700__ $$aDe Matteis, Mario 000128095 700__ $$aGalvañ, Joaquín 000128095 700__ $$aDuque Guerra, Alejandra 000128095 700__ $$aArias i Queralt, Laia 000128095 700__ $$aPerez-Bacigalupe, Maria 000128095 700__ $$aGonzalez-Ortega, Itxaso 000128095 700__ $$aToll, Alba 000128095 700__ $$aCasanovas, Francesc 000128095 700__ $$aSanchez-Pastor, Luis 000128095 700__ $$aValtueña, Mercedes 000128095 700__ $$aPomarol-Clotet, Edith 000128095 700__ $$aGarcía-León, Maria Ángeles 000128095 700__ $$aButjosa, Ana 000128095 700__ $$aRubio-Abadal, Elena 000128095 700__ $$aRibeiro, María 000128095 700__ $$aLópez-Ilundain, Jose M. 000128095 700__ $$aSaiz-Ruiz, Jeronimo 000128095 700__ $$aLeón-Quismondo, Luis 000128095 700__ $$aRivero, Olga 000128095 700__ $$0(orcid)0000-0001-5940-0357$$aRuiz, Pedro$$uUniversidad de Zaragoza 000128095 700__ $$aEchevarría, Rafael Segarra 000128095 700__ $$aGarcía-Portilla, M. Paz 000128095 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría 000128095 773__ $$g75 (2023), 80-92$$pEur. neuropsychopharmacol.$$tEUROPEAN NEUROPSYCHOPHARMACOLOGY$$x0924-977X 000128095 8564_ $$s949946$$uhttps://zaguan.unizar.es/record/128095/files/texto_completo.pdf$$yVersión publicada 000128095 8564_ $$s2107821$$uhttps://zaguan.unizar.es/record/128095/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000128095 909CO $$ooai:zaguan.unizar.es:128095$$particulos$$pdriver 000128095 951__ $$a2024-11-22-12:10:57 000128095 980__ $$aARTICLE